Vertex Pharmaceuticals Incorporated (VRTX)

276.17 -0.30%
Jun 29 close; Powered by IEX
Pros
Revenue growth higher than the industry and sector averages
Company’s profitability is improving
Forward PEG ratio low relative to industry peers
Buy analyst rating
Cons
Forward P/E ratio high relative to industry peers
Forward P/B ratio high relative to industry peers

Pros

  1. VRTX quarterly revenue growth was 27.30%, higher than the industry and sector average revenue growth (4.07% and 7.51%, respectively). See VRTX revenue growth chart.
  2. VRTX profitability is improving. The YoY profit margin change was 17.16 percentage points. See VRTX profitability chart.
  3. VRTX PEG ratio (P/E adjusted for growth) is 1.57, which is low compared to its industry peers’ PEG ratios. See VRTX PEG chart.
  4. VRTX average analyst rating is Buy. See VRTX analyst rating chart.

Cons

  1. VRTX forward P/E ratio is 20.43, which is high compared to its industry peers’ P/E ratios. See VRTX forward P/E ratio chart.
  2. VRTX Price/Book ratio is 7.36, which is high compared to its industry peers’ P/B ratios. See VRTX forward Price/Book ratio chart.